Render Target: STATIC
Render Timestamp: 2024-12-11T11:30:20.532Z
Commit: 611277b6de3cd1bb065350b6ef8d63df412b7185
XML generation date: 2024-09-30 01:59:00.600
Product last modified at: 2024-11-15T19:30:10.682Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

HSD17B13 (E5K7Q) Rabbit mAb #35371

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 30
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    HSD17B13 (E5K7Q) Rabbit mAb recognizes endogenous levels of total HSD17B13 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser103 of human HSD17B13 protein.

    Background

    HSD17B13, also known as hydroxysteroid 17-beta dehydrogenase 13, is a liver-enriched, hepatocyte-specific, lipid droplet-associated protein involved in the metabolism of steroid hormones (1). HSD17B13 has been linked to the development of non-alcoholic fatty liver disease (NAFLD), a condition characterized by the accumulation of fat in the liver that can lead to liver damage and inflammation (2). Hepatic expression of HSD17B13 is significantly upregulated in NAFLD patients relative to healthy individuals, with expression levels correlating with disease severity (3,4). Moreover, several loss-of-function variants in HSD17B13 are associated with a reduced risk of chronic liver disease and decreased disease severity of NAFLD. (5,6). These findings suggest that HSD17B13 may be a potential therapeutic target for the treatment of liver fibrosis and NAFLD.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.